

1 Clinical outcomes in patients infected with different SARS-CoV-2 variants at one
2 hospital during three phases of the COVID-19 epidemic in Marseille, France

3 Van Thuan Hoang^{1,2,3}, Philippe Colson^{2,4}, Anthony Levasseur^{2,4}, Jérémy Delerce², Jean-
4 Christophe Lagier^{2,4}, Philippe Parola^{1,2}, Matthieu Million^{2,4}, Pierre-Edouard Fournier^{1,2},
5 Didier Raoult^{2,4}, Philippe Gautret^{1,2*}

6 ¹Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France

7 ²IHU-Méditerranée Infection, Marseille, France

8 ³Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam

9 ⁴Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France

10 *Corresponding author:

11 Philippe Gautret

12 VITROME, Institut Hospitalo-Universitaire Méditerranée Infection, 19-21 Boulevard Jean
13 Moulin 13385 Marseille Cedex 05, France. Phone: + 33 (0) 4 13 73 24 01. Fax: + 33 (0) 4 13
14 73 24 02. E-mail address: philippe.gautret@club-internet.fr

Abstract (184/200 words)

Objectives: To compare the demographics, clinical characteristics and severity of patients infected with nine different SARS-CoV-2 variants, during three phases of the COVID-19 epidemic in Marseille.

Methods: A single centre retrospective cohort study was conducted in 1760 patients infected with SARS-CoV-2 of Nextstrain clades 20A, 20B, and 20C (first phase, February-May 2020)), Pangolin lineages B.1.177 (we named Marseille-2) and B.1.160 (Marseille-4) variants (second phase, June-December 2020)), and B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and A.27 (Marseille-501) variants (third phase, January 2021-today). Outcomes were the occurrence of clinical failures, including hospitalisation, transfer to the intensive-care unit, and death.

Results: During each phase, no major differences were observed with regards to age and gender distribution, the prevalence of chronic diseases, and clinical symptoms between variants circulating in a given phase. The B.1.177 and B.1.160 variants were associated with more severe outcomes. Infections occurring during the second phase were associated with a higher rate of death as compared to infections during the first and third phases. Patients in the second phase were more likely to be hospitalised than those in the third phase. Patients infected during the third phase were more frequently obese than others.

Conclusion: A large cohort study is recommended to evaluate the transmissibility and to better characterise the clinical severity of emerging variants.

Keywords: COVID-19; SARS-CoV-2; variant; mutation; 501Y; Marseille

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan in the Hubei province of China and causes the disease known as coronavirus disease 2019 (COVID-19). Since its emergence, SARS-CoV-2 has spread worldwide, and COVID-19 has caused the unprecedented disruption of human society. By 15 August 2021, the pandemic had infected over 205 million people and has led to the deaths of more than four million patients [1]. The presentation of the disease ranges from asymptomatic to severe and fatal forms, especially among older and vulnerable populations [2,3].

The diversity of the SARS-CoV-2 was initially reported to be very low [4]. However, variants, which differ from all other strains by sets of several (at least 5) mutations, in contrast with mutants that result from the progressive accumulation of mutations during viral replication and spread, have been reported since summer 2020, including in our geographical area [5]. In late December 2020, new variants of concern emerged, particularly those first described in the UK (named B.1.1.7 in Pangolin classification or alpha in WHO classification), South Africa (B.1.351 or beta), Brazil (P.1 or gamma) and India (B.1.167.2 or delta) [6,7], which have become major concerns. Indeed, their spike protein, which is the major target of immune responses elicited by previous infections or vaccination, may harbour several amino acid substitutions, including N501Y and E484K, or deletions that confer decreased sensitivity to antibodies [8].

Preliminary reports in the UK suggested that the alpha variant is more transmissible than previously circulating viruses, with increase in transmissibility estimated to be up to 75% [9]. The beta variant has also spread rapidly in South Africa. In addition, both variants have spread to several countries located in six WHO regions (<https://nextstrain.org/ncov/global>) [10]. The

SARS-CoV-2 gamma variant, initially identified in Manaus, Amazonas State, Brazil has also spread to various countries [10]. The delta variant was first detected in India in late 2020. It is thought to be partly responsible for India's second wave of the pandemic beginning in February 2021. It later contributed to a third wave in Fiji, the United Kingdom and South Africa [11]. To date, this variant affected 105 countries and more than 250,000 sequences were recorded (https://cov-lineages.org/global_report_B.1.617.2.html).

In Marseille, the first case of COVID-19 was recorded at the Institut Hospitalo-Universitaire Méditerranée Infection (IHU) on 27 February 2020 and the epidemic was characterised by three major phases. The first (phase 1) started in February and almost ended in May [5,12]. The second phase occurred suddenly at the end of June and lasted until December 2020. The third phase started in January 2021 and ended in June 2021. SARS-CoV-2 genomes were sequenced over time to characterise the genetic diversity of SARS-CoV-2. During the first phase of the epidemic, viruses of lineages 20A, 20B and 20C that are closely related to the initial Wuhan-Hu-1 isolate were predominantly circulating [12,13]. In January 2021, 14 variants, with clearly distinct genomic patterns, concomitantly or successively spread in the Marseille area [12,14], with three variants, including Marseille-1 (B.1.5.12.1 Pangolin lineage), Marseille-2 (B.1.177) and Marseille-4 (B.1.160), successively predominating [12,15]. The first case of a variant harbouring N501Y substitution (N501YV) was diagnosed in our institute on 31 December 2020, starting the third phase of the epidemic in Marseille. Up to June 2021, the alpha variant was the main variant circulating during this third phase, followed by the gamma variant, the Marseille-501 variant (A.27 Pangolin lineage) [16] and the beta variant (Figure 1). In a preliminary study, we observed that patients infected with 20A viruses of the first phase, B.1.5.12.1 and B.1.160 variants, and variants harbouring N501Y mutation presented different patterns of symptoms and

severity [5,12,14]. In this paper, we compare the demographics, clinical characteristics and severity of patients infected with nine different SARS-CoV-2 variants, during the three phases of the COVID-19 epidemic in Marseille.

Material and Methods

Data source

We conducted a single centre retrospective cohort study at the IHU Méditerranée Infection, Marseille (France), which is part of the network of public hospitals in Marseille (AP-HM). All available SARS-CoV-2 genome sequences obtained by our laboratory between March 2020 and April 2021 were reviewed. Patients infected with 20A, 20B, 20C viruses (circulating during the first phase of epidemic), B.1.177 or B.1.160 variants (circulating during the second phase), or different variants (N501YV) harbouring the N501Y substitution within the spike protein (circulating during the third phase of pandemic), were selected (Figure 1). Additional patients diagnosed with SARS-CoV-2 by real-time reverse-transcription PCR (qPCR) were included for whom viral genotype was determined by partial spike gene sequencing as previously described [16] or the Applied Biosystems TaqPath COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) or in house variant-specific qPCR as previously described [5, 17]. A second filter was applied to include only patients with information available on clinical status and follow-up. The B.1.5.12.1 variant that reached a very weak peak but represented up to 100% of infections during part of the month of July and then disappeared after a month-and-a-half has been described elsewhere [12].

Patients

The IHU received patients or asymptomatic contacts directly presenting for SARS-CoV-2 testing or samples sent from other wards in the Marseille Public University hospitals (AP-HM) (particularly in temporarily dedicated COVID-19 units and in intensive care units), or from laboratories outside the AP-HM. Most of the positive patients sampled at IHU were followed-up in the day clinic or were hospitalised in the Infectious Diseases department of the IHU, according to the severity of the disease. No detailed information was available for patients whose samples were sent to the IHU laboratory (Figure 2).

In this study, we only included 1760 patients who were seen at our institute in the day clinic or who were hospitalised in the conventional infectious disease units or other wards within the AP-HM. Demographic and clinical data including comorbidities were retrospectively retrieved from medical files including, notably, the main symptoms, in/outpatient status, transfer to intensive care unit (ICU), and death. At the time of writing, all patients had recovered and been discharged from hospital or had died. Because death could possibly occur long-time post-discharge, mortality was investigated through the national data on COVID-19 related mortality (at least 30 days post-discharge) [18]. Patients with missing information were mostly patients whose samples were sent to our laboratory by external medical facilities and who were therefore excluded.

Genome sequencing and assembling

All samples that were positive for SARS-CoV-2, identified by real-time PCR [19] with a cycle threshold (Ct) value <30, were processed for next-generation sequencing over time to characterise the genetic diversity of the virus. Whole genome sequencing was performed as previously described [12] from viral RNA extract obtained from 200 µL of nasopharyngeal swab fluid by reverse transcription by SuperScript IV (ThermoFisher Scientific, Waltham, MA, USA),

cDNA second strand synthesis using Klenow Fragment DNA polymerase (New England Biolabs, Beverly, MA, USA), and generated DNA purification with Agencourt AMPure XP beads (Beckman Coulter, Villepinte, France). Genome next-generation sequencing was performed using various techniques throughout the period of the SARS-CoV-2 pandemic: with the Illumina technology using the Nextera XT paired end strategy on MiSeq instruments between February 2020 and mid-March 2021 (Illumina Inc., San Diego, CA, USA), as previously described [5]; with the Oxford Nanopore technology on a GridION instrument between mid-March and mid-April 2021 (Oxford Nanopore Technologies Ltd., Oxford, UK), as previously described [20], after viral RNA reverse-transcription using SuperScript IV (ThermoFisher Scientific) then cDNA second strand synthesis with LunaScript RT SuperMix kit (New England Biolabs) and synthesized cDNA amplification using a multiplex PCR protocol with ARTIC nCoV-2019 V3 Panel primers (Integrated DNA technologies, Coralville, IA, USA) according to the ARTIC procedure (<https://artic.network/>); and with the Illumina COVIDSeq protocol on a NovaSeq 6000 instrument since mid-April 2021 (Illumina Inc., San Diego, CA, USA) following the manufacturer's instructions.

Genome assembly was performed using the CLC Genomics workbench v.7 software by mapping on the SARS-CoV-2 genome GenBank Accession no. NC_045512.2 (Wuhan-Hu-1 isolate). Recovered genomes were compared to sequences from the GISAID database (<https://www.gisaid.org/>). The phylogenetic analysis was performed using the nextstrain/ncov tool (<https://github.com/nextstrain/ncov>) that uses the IQ-TREE software [21] for phylogenetic tree building then the Auspice software for tree visualisation (<https://docs.nextstrain.org/projects/auspice/en/latest/releases/v2.html>).

Statistics

Statistical analyses were carried out using R [R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2020. URL: <https://www.Rproject.org/>] and Stata version 15.1 [<http://www.stata.com>]. Qualitative variables were presented by percentage. We used two approaches to conduct the analysis. The first one examined the demographics and clinical profiles of patients infected with different viral mutants or variants during each phase of the epidemic: 20A vs. 20B vs. 20C (first phase), B.1.177 vs. B.1.160 (second phase) and alpha vs. beta vs. gamma vs. A.27 (third phase). The second approach evaluated the difference in clinical outcomes, including hospitalisation, transfer to the ICU, and death among patients infected with SARS-CoV-2 from various lineages during the three phases (first phase vs. second phase vs. third phase). Unadjusted associations between multiple factors and groups of variants or clinical outcomes were examined by univariate analysis. Variables with p values <0.2 in the univariate analysis were included in the multivariate analysis [22]. The ϕ coefficient was used to test for multicollinearity among the independent variables. For pairs of variables that were highly correlated (absolute value of correlation coefficient >0.7), only one variable was entered into the multivariate model. Multivariate analysis was performed using exact logistic regression. The results were presented by percentages and odds ratio (OR), with a 95% confidence interval (95%CI). A p-value < 0.05 was considered as statistically significant.

Ethics Statement

Whole genome sequencing was performed on nasopharyngeal samples that were collected in the context of routine diagnosis. No additional samples were collected for this study. Clinical data were retrospectively retrieved from medical files and anonymised before analysis. Ethical

approval was obtained from the Marseille Institutional Review Board and Ethics Committee (No. 2020-016-03).

Results

Between 29 February 2020 and 14 April 2021, we identified 3,993 COVID-19 patients infected with nine variants, viral sequences being available from 3,965 of them, including a full-length genomes in 1,041 cases based on which a phylogeny was reconstructed (Figure 3). Clinical data were available from 1,760 of these 3,993 patients who were treated at our institute, including patients infected with 20A (N = 274), 20B (N = 65), and 20C (N = 95) viruses during the first phase, with B.1.177 (N = 69) and B.1.160 (N = 281) variants during the second phase, and alpha (N = 817), beta (N = 98), gamma (N = 20) and A.27 (N = 41) variants during the third phase (Supplementary table S1).

Patients with clinical data were older than patients without ($p < 0.0001$). No significant difference in gender was observed between the two groups ($p = 0.65$) (Supplementary table S1).

Comparison of patients infected with 20A, 20B and 20C viruses during the first phase of the epidemic.

Table 1 shows the characteristics of 434 patients infected with the three major clades circulating during the first phase of the COVID-19 epidemic in Marseille.

In multivariate analysis, patients infected with 20A and 20C viruses were significantly older than those infected with 20B viruses (p -value < 0.01 and < 0.05 , respectively). Patients infected with the 20A viruses were significantly more likely to present a rhinitis than those infected with the

20B viruses (OR = 1.83, P = 0.047) and were less likely to report a cough than those infected with 20C viruses (OR = 0.58, P = 0.03). Patients infected with 20A and 20B viruses were more likely to present a dyspnoea than patients infected with 20C viruses (OR = 2.35, P = 0.007 and OR = 2.42, P = 0.038, respectively). No significant differences in clinical outcomes, including rates of hospitalisation, transfer to ICU, and death, were observed between patients infected with viruses of these three clades.

Comparison of patients infected with B.1.177 and B.1.160 variants during the second phase of the epidemic.

Table 2 shows the characteristics of 350 patients infected with the two major variants circulating during the second phase of the COVID-19 epidemic in Marseille.

In multivariate analysis, patients infected with the B.1.177 variant were less likely to be hospitalised than those infected with the B.1.160 variant (OR = 0.52, P = 0.02). No significant differences in demographics, comorbidities, clinical profiles, transfer to the ICU, and mortality were observed.

Comparison of patients infected with alpha, beta, gamma and A.27 variants during the third phase of the epidemic.

Table 3 shows the characteristics of 976 patients infected with the four major variants circulating during the third phase of the COVID-19 epidemic in Marseille.

Patients infected with alpha and beta variants presented a relatively similar profile of demographic characteristics, comorbidities, and clinical symptoms in multivariate analysis (Table 4). Patients infected with the gamma variant were more frequently in the 45–64 years of

age group than those infected with the alpha (OR = 4.21, P = 0.006), beta (OR = 4.89, P = 0.005) or A.27 (OR = 4.17, P = 0.03) variants. Patients infected with the gamma variant were more likely to present with a cough than those infected with the beta variant (OR = 3.24, P = 0.028) and were more likely to report anosmia than those infected with the alpha (OR = 4.30, P = 0.003) and A.27 (OR = 8.33, P = 0.02) variants. No significant differences of clinical outcomes (hospitalisation, transfer to the ICU and death) were observed between patients infected with these four variants.

Comparison of COVID-19 patients during three phases of the epidemic.

Table 5 shows the characteristics of 1,760 patients infected during the three phases of the epidemic in Marseille.

In multivariate analysis, compared to patients in the first phase, those in the second phase were older (OR = 2.20, P <0.0001) and more likely to present with a fever (OR = 2.27, P <0.0001), but less likely to report a cough (OR = 0.69, P = 0.03) and rhinitis (OR = 0.37, P <0.0001). Patients in the second phase were also more likely to die than those in the first phase (OR = 1.91, P = 0.04). Compared to patients in the first phase, patients infected during the third phase were significantly older and less likely to report chronic heart diseases (OR = 0.40, P <0.0001) but more likely to report obesity (OR = 1.88, P = 0.001). They were more likely to present with a fever (OR = 1.94, P <0.0001), but less likely to report rhinitis and ageusia (OR = 0.51, P <0.0001 and OR = 0.46, P <0.0001, respectively). Finally, they were more frequently transferred to an ICU than those in the first phase (OR = 2.30, P = 0.03). Compared to patients in the third phase, patients infected during the second phase were more likely to report chronic heart diseases (OR = 1.83, P = 0.003) but less likely to report obesity (OR = 0.45, P <0.0001). They were more likely

to report ageusia (OR = 1.73, P = 0.005). Finally, they were more likely to be hospitalised and to die (OR = 1.98, P <0.0001 and OR = 3.01, P <0.0001, respectively), but were less likely to be transferred to an ICU (OR = 0.32, P <0.0001).

Discussion

SARS-CoV-2 is able to rapidly genetically diversify and can spread internationally through travellers and cause successive outbreaks. SARS-CoV-2 variants cause the COVID-19 disease with different clinical manifestations, even in populations who have previously been exposed to original viruses [23-25]. In this study, we compared the demographics, clinical profile, and outcomes of patients infected with different variants that circulated or continue to circulate in the Marseille area, where three major phases have occurred until June 2021. During each phase, no major differences were observed with regards to age and gender distribution, the prevalence of chronic diseases, and clinical symptoms between variants circulating during a given phase. The overall comparison between the three phases from March 2020 to April 2021 showed that the variants of the second phase (B.1.177 (Marseille-2) and B.1.160 (Marseille-4) lineages, respectively) were associated with more severe outcomes, leading to higher rates of hospitalisation and death. The appearance of the variants of concern harbouring the N501Y substitution at the end of December 2020 caught the attention of the World Health Organization because of faster spreading than other variants and the original viruses [9,10,26,27]. However, the association between these variants and severity of COVID-19 disease remains unclear [28]. In studies that analyzed community-based testing datasets, the alpha variant was significantly associated with an increase in hospitalisation and death [29-31]. In contrast, in a clinical study,

Frampton *et al.* showed that this variant was not associated with the severity of COVID-19 disease [27]. In addition, an analysis of UK COVID-19 Clinical Information Network data showed no higher risk of in-hospital deaths in patients infected with the alpha variant [32]. There was also no evidence of an increased risk for hospitalisation among patients infected with this variant [32]. Our observations corroborate other clinical studies. Patients infected during the third phase with variants harbouring the N501Y substitution were more frequently obese than others. We have no explanation for this association, and it is probably a random event.

Monitoring the epidemiology of SARS-CoV-2 variants is very important for epidemic control. As of 11 May 2021, 46,251 replacements in SARS-CoV-2 proteins were identified according to the CoV-GLUE online tool (<http://cov-glue.cvr.gla.ac.uk/#/replacement>). The highest numbers of these amino acid replacements are related to the NSP3 and S proteins, in 9,414 (20.4%) and 6,238 (13.5%) cases, respectively. Recently, the B.1.617 variant of SARS-CoV-2 emerged in Maharashtra, India and has since then spread to at least 17 countries (<https://www.gisaid.org/>). At the time of writing this manuscript, only a few cases had been documented in Marseille [33]. The presentation and severity of the disease may be very different depending on the SARS-CoV-2 variants, so the public health response needs to be adapted in real-time to the genomic profile of each viral epidemic phase.

This work has some limitations. We did not evaluate the transmissibility of different variants. The number of patients infected with different variants analysed in this work ranging from 20 to 817 may indirectly indicate the different degree of spread of the variants. In addition, we only analysed patients seen at our hospitals (IHU and AP-HM wards), requiring medical care with a viral load allowing successful virus genome sequencing. This could introduce a major selection bias. A large proportion of patients were excluded from our analysis because they were not

281 treated either at IHU or at AP-HM, and the actual severity of SARS-CoV-2 variants may differ
282 from our results. The patients who were not included here were significantly younger and could
283 have been asymptomatic or pauci-symptomatic. This selection bias is notably evidenced by the
284 significantly higher hospitalisation, transfer to ICU and mortality rates observed in patients
285 whose virus sequence was available, as compared to those of the overall population of COVID-
286 19 patients seen at our Institute with rates of hospitalisation of about 18%, of transfer to ICU of
287 about 2%, and with mortality of about 1% [34]. Moreover, access to care may vary according to
288 the phases of the epidemic and potentially influence the severity of the disease. In addition,
289 several biomarkers known to be associated with severity, including thrombopenia, D-dimer
290 counts, troponin level and lactate dehydrogenase [35], were not considered in this analysis.
291 Furthermore, we did not provide information on the duration of symptoms which could differ by
292 variant.

293 Nevertheless, our study is the largest clinical study to date that compared the clinical profiles of
294 nine lineages of SARS-CoV-2. A large cohort study is recommended to evaluate the
295 transmissibility and better characterise the clinical severity of emerging variants.

297 **Acknowledgments**

298 Our thanks go to Ludivine Brechard, Vera Esteves-Vieira, Elsa Prudent, Marielle Bedotto, Linda
299 Houhamdi and all the staff at the IHU Méditerranée Infection for their support with molecular
300 techniques.

301 **Funding**

This study was supported by the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, the French National Research Agency under the “Investissements d’avenir” programme, reference ANR-10-IAHU-03, the Région Provence Alpes Côte d’Azur and European FEDER PRIMI funding.

Conflicts of Interest

VTH, PC, AL, JD, JCL, PP, MM, PEF, DR and PG declare that they have no conflicts of interest.

References

- [1] COVID Live Update: 174,115,762 Cases and 3,745,384 Deaths from the Coronavirus - Worldometer n.d. <https://www.worldometers.info/coronavirus/> (accessed June 07, 2021).
- [2] COVID-19 severity | WHO Western Pacific n.d. <https://www.who.int/westernpacific/emergencies/covid-19/information/severity> (accessed May 11, 2021).
- [3] Gautret P, Million M, Jarrot P-A, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol* 2020;16:1159–84. <https://doi.org/10.1080/1744666X.2021.1847640>.
- [4] Fauver JR, Petrone ME, Hodcroft EB, Shioda K, Ehrlich HY, Watts AG, et al. Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. *Cell* 2020;181:990-996.e5. <https://doi.org/10.1016/j.cell.2020.04.021>.
- [5] Fournier PE, Colson P, Levasseur A, Gautret P, Bedotto M, Filosa V, et al. Genome sequence

analysis enabled deciphering the atypical evolution of COVID-19 epidemics in Marseille, France. Available at: <https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Capture-d%E2%80%99C3%A9cran-2021-02-02-%C3%A0-09.48.22.pdf>

[6] Faria NR, Claro IM, Candido D, Moyses Franco LA, Andrade PS, Coletti TM, et al.

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Available at: <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586>

[7] European Centre for Disease Prevention and Control, SARS-CoV-2 variants of concern as of 26 August 2021. Available at: <https://www.ecdc.europa.eu/en/covid-19/variants-concern> (accessed September 01, 2021)

[8] Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021;593:130–5. <https://doi.org/10.1038/s41586-021-03398-2>.

[9] Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update. European Centre for Disease Prevention and Control 2021. <https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update> (accessed May 11, 2021).

[10] Epidemiological Update: Variants of SARS-CoV-2 in the Americas - 24 March 2021 - PAHO/WHO | Pan American Health Organization n.d. <https://www.paho.org/en/documents/epidemiological-update-variants-sars-cov-2-americas-24-march-2021> (accessed May 11, 2021).

[11]. Callaway E. The mutation that helps Delta spread like wildfire. Nature.

2021;596(7873):472-473.

- [12] Colson P, Levasseur A, Gautret P, Fenollar F, Thuan Hoang V, Delerce J, et al. Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study. *Travel Med Infect Dis* 2021;40:101980. <https://doi.org/10.1016/j.tmaid.2021.101980>.
- [13] Colson P, Fournier PE, Chaudet H, Delerce J, Giraud-Gatineau A, Houhamdi L, Andrieu C, Brechard L, Bedotto M, Prudent E, Gazin C, Beye M, Burel E, Dudouet P, Tissot-Dupont H, Gautret P, Lagier JC, Million M, Brouqui P, Parola P, Drancourt M, La Scola B, Levasseur A, Raoult D. Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalisation and zoonosis in pandemics. *medRxiv* [Preprint] 2021. doi: <https://doi.org/10.1101/2021.09.10.21262922>
- [14] Dao TL, Hoang VT, Nguyen NN, Delerce J, Chaudet H, Levasseur A, et al. Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France. *Clin Microbiol Infect* 2021:S1198-743X(21)00270-6.
- [15] Fournier P-E, Colson P, Levasseur A, Devaux CA, Gautret P, Bedotto M, et al. Emergence and outcomes of the SARS-CoV-2 “Marseille-4” variant. *Int J Infect Dis* 2021;106:228–36. <https://doi.org/10.1016/j.ijid.2021.03.068>.
- [16]. Colson P, Levasseur A, Delerce J, Pinaul L, Dudouet P, Devaux C, Fournier PE, La Scola B, Lagier JC, Raoult D. Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage. Accepted in *Clin Microbiol Infect*.
- [17]. Bedotto M, Fournier PE, Houhamdi L, Colson P, Raoult D. Implementation of an in-house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y variants. *J Clin Virol*. 2021;140:104868. doi: 10.1016/j.jcv.2021.104868.

- [18] Institut National de la Statistique et des Etudes Economiques (INSEE). Fichier des personnes décédées. Available at : <https://www.data.gouv.fr/fr/datasets/fichier-des-personnes-decede-es/>
- [19] Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. *Travel Med Infect Dis* 2020;36:101632. <https://doi.org/10.1016/j.tmaid.2020.101632>.
- [20]. Colson P, Lagier JC, Baudoin JP, Bou Khalil J, La Scola B, Raoult D. Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. *Eur J Clin Microbiol Infect Dis*. 2020;39(8):1601-1603.
- [21] Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von HA, et al. IQTREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol Biol Evol* 2020;37:1530–4
- [22] Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code Biol Med* 2008;3:17. <https://doi.org/10.1186/1751-0473-3-17>.
- [23]. Zeyauallah M, AlShahrani AM, Muzammil K, Ahmad I, Alam S, Khan WH, et al. COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. *Front Genet*. 2021;12:693916.
- [24]. SeyedAlinaghi S, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. *Eur J Med Res*. 2021;26(1):51.

392 [25]. Gautret P, Houhamdi L, Nguyen NN, Hoang VT, Giraud-Gatineau A, Raoult D. Does
393 SARS-CoV-2 re-infection depend on virus variant? Clin Microbiol Infect. 2021 Jun
394 28;27(9):1374–5.

395 [26] Luring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2-What Do They Mean? JAMA
396 2021;325:529–31. <https://doi.org/10.1001/jama.2020.27124>.

397 [27] Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic
398 characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London,
399 UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 2021.
400 [https://doi.org/10.1016/S1473-3099\(21\)00170-5](https://doi.org/10.1016/S1473-3099(21)00170-5).

401 [28]. Dao TL, Hoang VT, Colson P, Lagier JC, Million M, Raoult D, Levasseur A, Gautret P.
402 SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants:
403 Current Evidence. J Clin Med. 2021 Jun 15;10(12). doi: 10.3390/jcm10122635.

404 [29] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of
405 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched
406 cohort study. BMJ 2021;372:n579. <https://doi.org/10.1136/bmj.n579>.

407 [30] Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP,
408 Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2
409 lineage B.1.1.7. Nature 2021. <https://doi.org/10.1038/s41586-021-03426-1>.

410 [31] Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, et al. Case fatality
411 risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5
412 February. Euro Surveill 2021;26. [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256)
413 [7917.ES.2021.26.11.2100256](https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256).

414 [32] NERVTAG paper on COVID-19 variant of concern B.1.1.7. GOVUK n.d.

<https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117> (accessed May 11, 2021).

[33] Scola BL, Fournier P-E, Colson P, Raoult D. SARS-CoV-2 variant from India to Marseille: the still active role of ports in the introduction of epidemics n.d.:5.

[34]. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. *Travel Med Infect Dis.* 2020 Jul-Aug;36:101791.

[35] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* 2020;58:1021–8. <https://doi.org/10.1515/cclm-2020-0369>.

Table 1: Characteristics of COVID-19 patients infected with clade 20A, 20B and 20C viruses during the first phase of the epidemic in Marseille (univariate and multivariate analysis).

	20A		20B		20C		20A vs. 20B		20A vs. 20C		20B vs. 20C	
	n	%	n	%	n	%	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value
	N = 274		N = 65		N = 95		Ref = 20B		Ref = 20C		Ref = 20C	
Sociodemographic characteristic												
Mean age \pm SD	49.1 \pm 20.4		39.2 \pm 17.2		48.9 \pm 16.7		NA	NA	NA	NA	NA	NA
Age <45	126	46.0	44	67.7	34	35.8	ref	ref	ref	ref	ref	ref
45-64	92	33.6	14	21.5	45	47.4	2.29 [1.18 – 4.43] 0.01	2.44 [1.25 – 4.75] 0.009	0.55 [0.33 – 0.93] 0.03	0.59 [0.36 – 0.96] 0.033	0.24 [0.11 – 0.51] <0.0001	0.22 [0.10 – 0.48] <0.0001
≥ 65	56	20.4	7	10.8	16	16.8	2.79 [1.19 – 6.58] 0.02	3.38 [1.40 – 8.14] 0.007	0.94 [0.48 – 1.85] 0.87	-	0.34 [0.13 – 0.91] 0.03	0.33 [0.12 – 0.91] 0.033
Gender Female	152	55.5	33	50.8	49	51.6	0.83 [0.46 – 1.48] 0.49	NA	0.85 [0.52 – 1.40] 0.51	NA	1.03 [0.52 – 2.04] 0.92	NA
Male	122	44.5	32	49.2	46	48.4						
Hypertension	56	20.4	5	7.7	18	19.0	3.08 [1.17 – 10.27] 0.02	-	1.10 [0.59 – 2.11] 0.75	NA	0.36 [0.10 – 1.08] 0.04	-
Diabetes	24	8.8	2	3.1	10	10.5	3.02 [0.72 – 27.01] 0.12	-	0.82 [0.36 – 1.99] 0.61	NA	0.27 [0.03 – 1.34] 0.08	-
Cancer	13	4.7	1	1.5	2	2.11	3.19 [0.46 – 137.53] 0.24	NA	2.32 [0.51 – 21.48] 0.26	NA	0.73 [0.01 – 14.26] 0.80	NA
Chronic respiratory disease	24	8.8	9	13.9	11	11.6	0.60 [0.25 – 1.55] 0.21	NA	0.73 [0.33 – 1.73] 0.42	NA	1.23 [0.42 – 3.49] 0.67	NA
Chronic heart disease	33	12.0	6	9.2	8	8.4	1.35 [0.52 – 4.11] 0.52	NA	1.49 [0.64 – 3.87] 0.33	NA	1.11 [0.30 – 3.85] 0.86	NA

Obesity	28	10.2	8	12.3	10	10.5	0.81 [0.33 – 2.17] 0.62	NA	0.97 [0.43 – 2.33] 0.93	NA	1.19 [0.38 – 3.59] 0.73	NA
Clinical signs												
Fever	75	27.4	20	30.8	23	24.2	0.85 [0.46 – 1.62] 0.58	NA	1.18 [0.67 – 2.13] 0.55	NA	1.39 [0.64 – 3.00] 0.36	NA
Cough	133	48.5	36	55.4	57	60.0	0.76 [0.42 – 1.35] 0.32	NA	0.63 [0.38 – 1.04] 0.054	0.58 [0.36 – 0.95] 0.03	0.83 [0.42 – 1.65] 0.56	NA
Rhinitis	113	41.2	21	32.3	34	35.8	1.47 [0.80 – 2.75] 0.19	1.83 [1.01 – 3.31] 0.047	1.26 [0.76 – 2.11] 0.35	NA	0.86 [0.41 – 1.76] 0.65	NA
Dyspnoea	79	28.8	18	27.7	15	15.8	1.06 [0.56 – 2.06] 0.86	NA	2.16 [1.15 – 4.28] 0.01	2.35 [1.26 – 4.39] 0.007	2.04 [0.88 – 4.79] 0.07	2.42 [1.05 – 5.58] 0.038
Anosmia	78	28.6	14	21.5	21	22.1	1.46 [0.74 – 3.02] 0.25	NA	1.41 [0.79 – 2.58] 0.22	NA	0.97 [0.41 – 2.21] 0.93	NA
Ageusia	73	26.7	16	24.6	20	21.1	1.12 [0.58 – 2.24] 0.73	NA	1.37 [0.76 – 2.54] 0.27	NA	1.22 [0.54 – 2.76] 0.60	NA
Hypoxemia	55	20.1	7	10.8	15	15.8	2.08 [0.88 – 5.69] 0.08	-	1.34 [0.70 – 2.70] 0.36	NA	0.64 [0.21 – 1.81] 0.37	NA
Clinical outcomes												
Hospitalisation	63	23.0	15	23.1	26	27.4	0.99 [0.51 – 2.04] 0.99	NA	0.79 [0.45 – 1.41] 0.39	NA	0.80 [0.35 – 1.75] 0.54	NA
ICU	5	1.8	1	1.5	3	3.2	1.19 [0.13 – 57.12] 0.87	NA	0.57 [0.11 – 3.75] 0.44	NA	0.48 [0.01 – 6.15] 0.52	NA
Death	11	4.0	2	3.1	3	3.2	1.32 [0.28 – 12.52] 0.72	NA	1.28 [0.33 – 7.31] 0.71	NA	0.97 [0.08 – 8.75] 0.98	NA

Ref: reference, NA: not applicable, -: non-significant

Table 2: Characteristics of COVID-19 patients infected with Marseille-2 (B.1.177 lineage) and Marseille-4 (B.1.160 lineage) variants during the second phase of the epidemic in Marseille (univariate and multivariate analysis).

	B.1.177		B.1.160		B.1.177 vs. B.1.160	
	n	%	n	%	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value
	N = 69		N = 281		Ref = B.1.160	
Sociodemographic characteristic						
Mean age	56.0 ± 21.6		58.3 ± 23.1		NA	NA
Age <45	24	34.8	74	26.3	ref	ref
45-64	19	27.5	88	31.3	0.67 [0.34 – 1.31] 0.24	NA
≥ 65	26	37.7	119	42.4	0.67 [0.36 – 1.26] 0.22	NA
Gender Female	38	55.1	127	45.2	0.67 [0.38 – 1.18] 0.14	-
Male	31	44.9	154	54.8		
Hypertension	17	24.6	86	30.6	0.74 [0.38 – 1.39] 0.33	NA
Diabetes	5	7.3	49	17.4	0.37 [0.11 – 0.98] 0.04	-
Cancer	8	11.6	27	9.6	1.23 [0.46 – 2.97] 0.62	NA
Chronic respiratory disease	5	7.3	37	13.2	0.52 [0.15 – 1.39] 0.18	-
Chronic heart disease	14	20.3	55	19.6	1.05 [0.50 – 2.08] 0.89	NA
Obesity	8	11.6	27	9.6	1.23 [0.46 – 2.97] 0.62	NA
Clinical signs						
Fever	27	39.1	121	43.1	0.85 [0.48 – 1.50] 0.55	NA
Cough	28	40.6	106	37.7	1.13 [0.63 – 1.99] 0.66	NA
Rhinitis	10	14.5	45	16.0	0.89 [0.38 – 1.92] 0.76	NA

Dyspnoea	17	24.6	71	25.3	0.97 [0.49 – 1.83] 0.91	NA
Anosmia	11	15.9	39	13.9	1.17 [0.51 – 2.51] 0.67	NA
Ageusia	9	13.0	38	13.6	0.96 [0.38 – 2.15] 0.91	NA
Hypoxemia	17	24.6	86	30.6	0.74 [0.38 – 1.39] 0.33	NA
Clinical outcomes						
Hospitalisation	21	30.4	129	45.9	0.52 [0.28 – 0.93] 0.02	0.52 [0.29 – 0.91] 0.02
ICU	2	2.9	16	5.7	0.49 [0.05 – 2.19] 0.35	NA
Death	8	11.6	44	15.7	0.71 [0.27 – 1.62] 0.40	NA

Ref: reference, NA: not applicable, -: non-significant

Table 3. Characteristics of COVID-19 patients infected with the alpha, beta, gamma and A.27 variants during the third phase of the epidemic in Marseille (univariate analysis).

	Alpha N = 817	Beta N = 98	Gamma N = 20	A.27 N = 41	Alpha vs. beta	Gamma vs. alpha	Gamma vs. beta	A.27 vs. alpha	A.27 vs. beta	A.27 vs. gamma
	n (%)	n (%)	n (%)	n (%)	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value
					Ref = beta	Ref = alpha	Ref = beta	Ref = alpha	Ref = beta	Ref = gamma
Sociodemographic characteristic										
Mean age	54.6 ± 17.5	52.9 ± 19.0	52.6 ± 13.7	56.0 ± 19.2	NA	NA	NA	NA	NA	NA
Age										
<45	229 (28.0)	29 (29.6)	3 (15.0)	12 (29.3)	ref	ref	ref	ref	ref	ref
45 – 64	340 (41.6)	39 (39.8)	15 (75.0)	15 (36.6)	1.10 [0.66 – 1.84] 0.70	3.37 [0.96 – 11.76] 0.06	3.72 [0.98 – 14.05] 0.053	0.84 [0.39 – 1.83] 0.66	0.93 [0.38 – 2.28] 0.87	0.25 [0.06 – 1.07] 0.06
≥ 65	248 (30.4)	30 (30.6)	2 (10.0)	14 (34.1)	1.05 [0.61 – 1.80] 0.87	0.62 [0.10 – 3.72] 0.60	0.64 [0.10 – 4.14] 0.64	1.08 [0.49 – 2.38] 0.85	1.13 [0.45 – 2.84] 0.80	1.75 [0.25 – 12.28] 0.57
Gender										
Female	404 (49.5)	48 (49.0)	8 (40.0)	22 (53.7)	ref	ref	ref	ref	ref	ref
Male	413 (50.5)	50 (51.0)	12 (60.0)	19 (46.3)	0.98 [0.63 – 1.53] 0.93	1.47 [0.54 – 4.18] 0.40	1.44 [0.49 – 4.43] 0.46	0.84 [0.43 – 1.66] 0.60	0.83 [0.37 – 1.83] 0.61	0.58 [0.17 – 1.93] 0.32
Hypertension	226 (27.7)	30 (30.6)	5 (25.0)	11 (26.8)	0.87 [0.54 – 1.42] 0.54	0.87 [0.25 – 2.56] 0.79	0.76 [0.20 – 2.46] 0.62	0.96 [0.43 – 2.01] 0.91	0.83 [0.33 – 2.00] 0.66	1.10 [0.28 – 4.79] 0.88
Diabetes	109 (13.3)	10 (10.2)	2 (10.0)	5 (12.2)	1.35 [0.68 – 3.01] 0.38	0.72 [0.08 – 3.08] 0.66	0.98 [0.10 – 5.20] 0.98	0.90 [0.27 – 2.38] 0.83	1.22 [0.31 – 4.26] 0.73	1.25 [0.18 – 14.29] 0.80
Cancer	54 (6.6)	6 (6.1)	0 (0)	4 (9.8)	1.09 [0.45 – 3.17] 0.85	NA	NA	1.53 [0.38 – 4.49] 0.43	1.66 [0.32 – 7.43] 0.45	NA
Chronic respiratory disease	100 (12.2)	12 (12.2)	2 (10.0)	1 (2.4)	1.00 [0.52 – 2.08] 1.00	0.80 [0.09 – 3.41] 0.76	0.80 [0.08 – 4.08] 0.78	0.18 [0.01 – 1.08] 0.06	0.18 [0.01 – 1.30] 0.07	0.23 [0.01 – 4.70] 0.19
Chronic heart disease	72 (8.8)	10 (10.2)	0 (0)	2 (4.9)	0.85 [0.42 – 1.92]	NA	NA	0.53 [0.06 – 2.13]	0.45 [0.05 – 2.28]	NA

					0.65 1.62 [0.87 – 3.24] 0.12	1.35 [0.38 – 2.78] 0.94	2.18 [0.53 – 7.76] 0.18	0.38 0.98 [0.38 – 2.22] 0.96	0.31 0.16 [0.52 – 4.57] 0.35	0.73 [0.17 – 3.34] 0.62
Obesity	162 (19.8)	13 (13.3)	5 (25.0)	8 (19.5)						
Clinical signs										
Fever	361 (44.2)	34 (34.7)	9 (45.0)	13 (31.7)	1.49 [0.94 – 2.38] 0.07	1.03 [0.37 – 2.78] 0.94	1.54 [0.51 – 4.53] 0.38	0.59 [0.27 – 1.19] 0.12	0.87 [0.37 – 2.02] 0.73	0.57 [0.17 – 1.98] 0.31
Cough	384 (47.0)	38 (38.8)	13 (65.0)	16 (39.0)	1.40 [0.89 – 2.21] 0.12	2.09 [0.77 – 6.26] 0.11	2.93 [0.97 – 9.42] 0.03	0.72 [0.35 – 1.43] 0.32	1.01 [0.44 – 2.27] 0.98	0.34 [0.10 – 1.19] 0.06
Rhinitis	176 (21.5)	16 (16.3)	3 (15.0)	10 (24.4)	1.41 [0.79 – 2.64] 0.23	0.64 [0.12 – 2.26] 0.48	0.90 [0.15 – 3.70] 0.88	1.17 [0.50 – 2.52] 0.67	1.65 [0.60 – 4.36] 0.27	1.83 [0.39 – 11.62] 0.40
Dyspnoea	211 (25.8)	25 (25.5)	4 (20.0)	7 (17.1)	1.02 [0.62 – 1.72] 0.95	0.72 [0.17 – 2.26] 0.56	0.73 [0.16 – 2.57] 0.60	0.59 [0.22 – 1.38] 0.21	0.60 [0.20 – 1.62] 0.28	0.82 [0.18 – 4.42] 0.78
Anosmia	91 (11.1)	15 (15.5)	7 (35.0)	2 (4.9)	0.69 [0.37 – 1.34] 0.21	4.30 [1.41 – 11.91] 0.001	2.94 [0.84 – 9.53] 0.04	0.41 [0.05 – 1.63] 0.21	0.28 [0.03 – 1.31] 0.08	0.10 [0.01 – 0.61] 0.002
Ageusia	83 (10.2)	12 (12.4)	5 (25.0)	2 (4.9)	0.80 [0.41 – 1.68] 0.50	2.95 [0.82 – 8.80] 0.03	2.36 [0.56 – 8.54] 0.14	0.45 [0.05 – 1.81] 0.27	0.36 [0.04 – 1.76] 0.18	0.15 [0.01 – 1.10] 0.02
Hypoxemia	199 (24.4)	30 (30.6)	3 (15.0)	11 (26.8)	0.73 [0.45 – 1.20] 0.18	0.55 [0.10 – 1.92] 0.33	0.40 [0.07 – 1.55] 0.16	1.14 [0.51 – 2.39] 0.72	0.83 [0.33 – 2.00] 0.66	2.08 [0.45 – 13.05] 0.30
Clinical outcomes										
Hospitalisation	203 (24.9)	31 (31.6)	4 (20.0)	11 (26.8)	0.71 [0.45 – 1.17] 0.15	0.76 [0.18 – 2.38] 0.62	0.54 [0.12 – 1.88] 0.30	1.11 [0.49 – 2.33] 0.77	0.79 [0.32 – 1.89] 0.57	1.47 [0.35 – 7.31] 0.56
ICU	58 (7.1)	9 (9.2)	2 (10.0)	2 (4.9)	0.76 [0.36 – 1.80] 0.45	1.45 [0.16 – 6.31] 0.62	1.10 [0.11 – 5.98] 0.91	0.67 [0.08 – 2.71] 0.59	0.51 [0.05 – 2.63] 0.39	0.46 [0.03 – 6.93] 0.45
Death	34 (4.2)	0 (0)	0 (0)	4 (9.8)	NA	NA	NA	2.49 [0.61 – 7.52] 0.09	NA	NA

SdA: South African, Ref: reference, NA: not applicable

Table 4. Characteristics of COVID-19 patients infected with the alpha, beta, gamma and A-27 (Marseille-501) variants during the third phase of the epidemic in Marseille (multivariate analysis).

	Alpha vs. beta	Gamma vs. alpha	Gamma vs. beta	A.27 vs. alpha	A.27 vs. beta	A.27 vs. gamma
	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value	OR [95%CI] P-value
	Ref = beta	Ref = alpha	Ref = beta	Ref = alpha	Ref = beta	Ref = gamma
Sociodemographic characteristic						
Age						
<45	NA	ref	ref	ref	ref	ref
45 – 64	NA	4.21 [1.51 – 11.77] 0.006	4.89 [1.59 – 14.98] 0.005	NA	NA	0.24 [0.07 – 0.83] 0.03
≥ 65	NA	-	NA	NA	NA	-
Gender						
Female						
Male	NA	NA	NA	NA	NA	NA
Hypertension	NA	NA	NA	NA	NA	NA
Diabetes	NA	NA	NA	NA	NA	NA
Cancer	NA	NA	NA	NA	NA	NA
Chronic respiratory disease	NA	NA	NA	-	-	-
Chronic heart disease	NA	NA	NA	NA	NA	NA
Obesity	-	NA	-	NA	NA	NA
Clinical signs						
Fever	-	NA	NA	-	NA	NA
Cough	-	-	3.24 [1.13 – 9.28] 0.028	NA	NA	-
Rhinitis	NA	NA	NA	NA	NA	NA
Dyspnoea	NA	NA	NA	NA	NA	NA
Anosmia	NA	4.30 [1.66 – 11.19] 0.003	-	NA	-	0.12 [0.02 – 0.73] 0.02
Ageusia	NA	-	-	NA	-	-
Hypoxemia	-	NA	-	NA	NA	NA
Clinical outcomes				NA	NA	
Hospitalisation	-	NA	NA	NA	NA	NA
ICU	NA	NA	NA	NA	NA	NA
Death	NA	NA	NA	-	NA	NA

SdA: South African, Ref: reference, NA: not applicable, -: non-significant

Table 5: Characteristics of COVID-19 patients during the three phases of the epidemic in Marseille (univariate and multivariate analysis).

	First phase		Second phase		Third phase		Second phase vs. first phase		Third phase vs. first phase		Second phase vs. third phase	
	N = 434		N = 350		N = 976							
	n	%	n	%	n	%	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value	Univariate analysis OR [95%CI] P-value	Multivariate analysis OR [95%CI] P-value
			N = 350				Ref = first phase		Ref = first phase		Ref = third phase	
Sociodemographic characteristic												
Mean age	47.5 ± 19.5		57.8 ± 22.8		54.4 ± 17.7		NA	NA	NA	NA	NA	NA
Age <45	204	47.0	98	28.0	273	28.0	ref	ref	ref	ref	ref	ref
45-64	151	34.8	107	30.6	409	41.9	1.48 [1.04 – 2.08] 0.03	-	2.02 [1.56 – 2.63] <0.0001	1.75 [1.32 – 2.30] <0.0001	0.73 [0.53 – 0.99] 0.048	-
≥ 65	79	18.2	145	41.4	294	30.1	3.82 [2.65 – 5.50] <0.0001	2.20 [1.54 – 3.14] <0.0001	2.78 [2.04 – 3.78] <0.0001	2.45 [1.71 – 3.49] <0.0001	1.37 [1.01 – 1.86] 0.04	-
Gender Female	234	53.9	165	47.1	482	49.4	ref	ref	ref	ref	ref	ref
Male	200	46.1	185	52.9	494	50.6	1.31 [0.98 – 1.76] 0.06	-	1.20 [0.95 – 1.51] 0.12	-	1.09 [0.85 – 1.41] 0.47	NA
Hypertension	79	18.2	103	29.4	272	27.9	1.87 [1.32 – 2.66] 0.0002	-	1.74 [1.30 – 2.33] 0.0001	-	1.08 [0.82 – 1.42] 0.58	NA
Diabetes	36	8.3	54	15.4	126	12.9	2.01 [1.17 – 3.25] 0.002	-	1.64 [1.10 – 2.49] 0.01	-	1.23 [0.85 – 1.76] 0.24	NA
Cancer	16	3.7	35	10.0	64	6.6	2.90 [1.53 – 5.71] 0.0004	-	1.83 [1.03 – 3.44] 0.03	-	1.58 [0.99 – 2.48] 0.04	-
Chronic respiratory disease	44	10.1	42	12.0	115	11.8	1.21 [0.75 – 1.94] 0.41	NA	1.18 [0.81 – 1.75] 0.37	NA	1.02 [0.68 – 1.50] 0.91	NA
Chronic heart disease	47	10.8	69	19.7	84	8.6	2.02 [1.33 – 3.09] 0.0005	-	0.78 [0.52 – 1.16] 0.18	0.40 [0.26 – 0.61] <0.0001	2.61 [1.81 – 3.73] <0.0001	1.83 [1.23 – 2.70] 0.003

Obesity	46	10.6	35	10.0	188	19.3	0.94 [0.57 – 1.53] 0.78	NA	2.01 [1.41 – 2.91] 0.0001	1.88 [1.31 – 2.70] 0.001	0.47 [0.31 – 0.69] 0.0001	0.45 [0.30 – 0.67] <0.0001
Clinical signs												
Fever	118	27.2	148	42.3	417	42.7	1.96 [1.44 – 2.68] <0.0001	2.27 [1.60 – 3.11] <0.0001	2.00 [1.55 – 2.58] <0.0001	1.94 [1.50 – 2.52] <0.0001	0.98 [0.76 – 1.27] 0.89	NA
Cough	226	52.1	134	38.3	451	46.2	0.57 [0.42 – 0.77] 0.0001	0.69 [0.50 – 0.96] 0.03	0.79 [0.63 – 0.99] 0.04	-	0.72 [0.56 – 0.93] 0.01	-
Rhinitis	168	38.7	55	15.7	205	21.0	0.30 [0.20 – 0.42] <0.0001	0.37 [0.26 – 0.54] <0.0001	0.42 [0.33 – 0.54] <0.0001	0.51 [0.39 – 0.67] <0.0001	0.70 [0.50 – 0.98] 0.03	-
Dyspnoea	112	25.8	88	25.1	247	25.3	0.97 [0.69 – 1.35] 0.83	NA	0.97 [0.75 – 1.27] 0.84	NA	0.99 [0.74 – 1.32] 0.95	NA
Anosmia	113	26.1	50	14.3	115	11.8	0.47 [0.32 – 0.69] 0.0001	-	0.38 [0.28 – 0.51] <0.0001	-	1.25 [0.86 – 1.81] 0.22	NA
Ageusia	109	25.2	47	13.5	102	10.5	0.46 [0.31 – 0.68] <0.0001	-	0.35 [0.25 – 0.47] <0.0001	0.46 [0.34 – 0.64] <0.0001	1.33 [0.90 – 1.95] 0.13	1.73 [1.18 – 2.54] 0.005
Hypoxemia	77	17.7	103	29.4	243	24.9	1.93 [1.36 – 2.75] 0.0001	-	1.54 [1.15 – 2.07] 0.003	-	1.26 [0.95 – 1.66] 0.10	-
Clinical outcomes												
Hospitalisation	104	24.0	150	42.9	249	25.5	2.38 [1.73 – 3.27] <0.0001	-	1.09 [0.83 – 1.43] 0.54	NA	2.19 [1.68 – 2.85] <0.0001	1.98 [1.43 – 2.74] <0.0001
ICU	9	2.1	18	5.1	71	7.3	2.56 [1.07 – 6.55] 0.02	-	3.70 [1.82 – 8.51] 0.0001	2.30 [1.11 – 4.78] 0.03	0.69 [0.38 – 1.19] 0.17	0.32 [0.18 – 0.58] <0.0001
Death	16	3.7	52	14.9	38	3.9	4.56 [2.50 – 8.71] <0.0001	1.91 [1.02 – 3.59] 0.04	1.06 [0.57 – 2.06] 0.85	NA	4.31 [2.72 – 6.86] <0.0001	3.01 [1.81 – 5.01] <0.0001


Ref: reference, NA: not applicable, -: non significant

Figure 1: Weekly distribution of SARS-CoV-2 genotypes

Figure 2: Flow-chart of study

Figure 3: Phylogeny reconstruction based on the SARS-CoV-2 genomes recovered from 1,041 patients. The genome of the original Wuhan-Hu-1 coronavirus isolate (GenBank accession no. NC_045512.2) was incorporated in the tree. Major SARS-CoV-2 variants are labelled. MRS-4, B.1.160 (Marseille-4); 20H (South Africa), B.1.351 (Beta); 20I (UK), B.1.1.7 (Alpha); 20J (Brazil), P.1 (Gamma); MRS-2, B.1.1.177 (Marseille-2); MRS-501, A.27 (Marseille-501).

Proportions of the different SARS-CoV-2 variants among all genomes analyzed



3993 patients with successful SARS-CoV-2 sequences
(385 with clade 20A, 99 with 20B, 124 with 20C, 145 with Marseille-2, 616 with Marseille-4, 2254 with UK, 258 with South Africa, 24 with Brazilian, 88 with Marseille-501)

INCLUSION

1760 patients seen at the outpatient clinic or hospitalized with available clinical data (274 with clade 20A, 65 with 20B, 95 with 20C, 69 with Marseille-2, 281 with Marseille-4, 817 with UK, 98 with South Africa, 20 with Brazilian, 41 with Marseille-501)

Demographic and clinical data were retrospectively retrieved from medical files

EXCLUSION

2233 patients with missing data or whose samples were sent to laboratory by external medical structures

